Developmental Research Program

发展研究计划

基本信息

项目摘要

The MSCP SPORE Developmental Research Program (DRP) provides seed funding to explore promising novel research in melanoma and other skin cancers, particularly by investigators not currently engaged in research in this area. The DRP solicits proposals twice a year and to use a peer-reviewed scoring system to prioritize proposals for funding. The DRP Directors and Executive Committee, Internal Advisory Board and External Advisory Board participate in the review process, together with the Patient Advocates and any additional experts who may be called upon if special reviewer expertise is necessary. During the past grant period, the MSCP SPORE funded 9 DRP projects in basic, translational, and clinical research. The DRP Directors track the progress of the successful applications and assign mentors to funded investigators to ensure that they obtain any needed services from the MSCP SPORE Cores (Administrative Core A, Biospecimen Core B, Biostatistics Core C, and Informatics Core D) and that they are effectively integrated into the SPORE program. Awardees present their research results to the SPORE investigators after one year of funding to be eligible for a second year of support. Progress toward translation as well as impact and innovation will determine whether DRP projects are found to merit promotion to full SPORE projects; in the past funding period, productive and innovative research funded by DRP awards to Drs. Hassane Zarour and Soldano Ferrone has been promoted to a full project. Project 3, in this renewal application. Awardees are also advised as appropriate in the preparation of grant applications for funding outside the SPORE mechanism and given access to SPORE Core resources to aid in this endeavor. DRP-supported research has led to 3 NCI awards (R01CA154728, R01CA157467, R01CA169118) and a pilot award funded by the University of Pittsburgh Clinical Translational Science Institute Basic to Clinical Collaborative Research Pilot Program. There are also several grant applications submitted or planned based on DRP results from the previous grant period, including an R21 and two additional R01 applications.
MSCP SPORE发展研究计划(DRP)提供种子资金,以探索黑色素瘤和其他皮肤癌的有前途的新研究,特别是目前未从事该领域研究的研究人员。DRP每年征集两次提案,并使用同行评审的评分系统来确定供资提案的优先次序。DRP董事和执行委员会、内部咨询委员会和外部咨询委员会与患者倡导者以及在需要特殊评审专家时可能需要的任何其他专家一起参与评审过程。在过去的资助期间,MSCP SPORE资助了9个DRP项目,涉及基础,转化和临床研究。的DRP 董事会跟踪成功申请的进展情况,并为受资助的研究者指派导师,以确保他们从MSCP SPORE核心(管理核心A、生物标本核心B、生物统计核心C和信息学核心D)获得任何所需的服务,并确保他们有效地融入SPORE计划。获奖者在获得一年的资助后向SPORE调查人员展示他们的研究成果,以便有资格获得第二年的支持。翻译的进展以及影响和创新将决定DRP项目是否值得推广到完整的SPORE项目;在过去的资助期间,DRP资助的富有成效和创新的研究授予Hassane Zarour博士和 索尔达诺·费隆已经被提升为一个完整的项目。项目3,在此更新申请。获奖者还建议在适当的准备拨款申请的资助以外的SPORE机制,并给予访问SPORE核心资源,以帮助在这奋进的努力。DRP支持的研究已经获得了3个NCI奖项(R 01 CA 154728,R 01 CA 157467,R 01 CA 169118)和一个由匹兹堡大学临床转化科学研究所基础到临床合作研究试点计划资助的试点奖。还有几个赠款申请提交或计划的基础上DRP结果从上一个赠款期,包括一个R21和两个额外的R 01申请。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John Munn Kirkwood其他文献

John Munn Kirkwood的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John Munn Kirkwood', 18)}}的其他基金

Melanoma and Skin Cancer Program SPORE
黑色素瘤和皮肤癌计划 SPORE
  • 批准号:
    10270227
  • 财政年份:
    2021
  • 资助金额:
    $ 2.32万
  • 项目类别:
Melanoma and Skin Cancer Program SPORE
黑色素瘤和皮肤癌计划 SPORE
  • 批准号:
    10469631
  • 财政年份:
    2021
  • 资助金额:
    $ 2.32万
  • 项目类别:
Melanoma and Skin Cancer Program SPORE
黑色素瘤和皮肤癌计划 SPORE
  • 批准号:
    10683750
  • 财政年份:
    2021
  • 资助金额:
    $ 2.32万
  • 项目类别:
Training Program in Skin Biology and Cancer
皮肤生物学和癌症培训计划
  • 批准号:
    9272850
  • 财政年份:
    2014
  • 资助金额:
    $ 2.32万
  • 项目类别:
Training Program in Skin Biology and Cancer
皮肤生物学和癌症培训计划
  • 批准号:
    8607635
  • 财政年份:
    2014
  • 资助金额:
    $ 2.32万
  • 项目类别:
Training Program in Skin Biology and Cancer
皮肤生物学和癌症培训计划
  • 批准号:
    8857377
  • 财政年份:
    2014
  • 资助金额:
    $ 2.32万
  • 项目类别:
Pilot Clinical & Molecular Analysis of Atypical Nevus Response to Sulforaphane
试点临床
  • 批准号:
    8302813
  • 财政年份:
    2012
  • 资助金额:
    $ 2.32万
  • 项目类别:
Pilot Clinical & Molecular Analysis of Atypical Nevus Response to Sulforaphane
试点临床
  • 批准号:
    8509629
  • 财政年份:
    2012
  • 资助金额:
    $ 2.32万
  • 项目类别:
SPORE in Skin Cancer
皮肤癌中的孢子
  • 批准号:
    8548580
  • 财政年份:
    2008
  • 资助金额:
    $ 2.32万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    8933150
  • 财政年份:
    2008
  • 资助金额:
    $ 2.32万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 2.32万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 2.32万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 2.32万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.32万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 2.32万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 2.32万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 2.32万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 2.32万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 2.32万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 2.32万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了